

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

INSIDE INFORMATION ESTABLISHMENT OF NEW FACILITY IN SINGAPORE

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company plans to establish a new biologics clinical and commercial manufacturing facility in Singapore (the “**Singapore New Facility**”) which, according to the Company’s preliminary development plan, may involve a total investment amount of approximately S\$80 million (equivalent to approximately HK\$467 million) and hiring of approximately 150 employees. It is intended that the Singapore New Facility will be constructed with a total of 4,500L bioreactor capacity, where two 2,000L traditional fed-batch and one 500L perfusion based continuous processing will be installed for the purpose of handling both clinical and small volume commercial production. In light of Singapore’s reputation as one of the leaders in the biopharmaceutical industry, the Board believes that the Singapore New Facility will play a key role in the Group’s global biomanufacturing network not only to enable local companies to expedite biologics development in Asia, but also to ensure that biologics are manufactured by the Group to the highest quality and with a robust supply chain to benefit patients worldwide.

The Board is of the view that the proposed construction of the Singapore New Facility, which is intended to be for the Group's own use in the ordinary and usual course of business, is in the interests of the Company as well as its shareholders as a whole. Further announcement(s) will be made by the Company in accordance with the applicable requirements under the Listing Rules as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, May 22, 2018

As of the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Mr. Edward Hu, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Wo Felix Fong as independent non-executive Directors.

** For identification purpose only*